Alector, Inc. (ALEC) stock
ALECNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.30−0.27 (-10.51%)
Close on Nov 19, 2026Market cap $256.81MP/E –Yield –
Alector free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Alector's free cash flow for the twelve months ending Jun 30, 2026 was -$158.39M. For fiscal 2025 it was -$184.07M. The highest annual figure on record is $295.30M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$184.07M | – |
| FY2024 | Dec 31, 2024 | -$231.16M | – |
| FY2023 | Dec 31, 2023 | -$186.54M | – |
| FY2022 | Dec 31, 2022 | -$24.45M | -108.3% |
| FY2021 | Dec 31, 2021 | $295.30M | – |
| FY2020 | Dec 31, 2020 | -$171.77M | – |
| FY2019 | Dec 31, 2019 | -$114.57M | -191.2% |
| FY2018 | Dec 31, 2018 | $125.58M | – |
| FY2017 | Dec 31, 2017 | -$18.57M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$34.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$49.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$41.69M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$49.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$60.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$55.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$50.95M | – |
| Q2 FY2024 | Jun 30, 2024 | -$63.13M | – |
| Q1 FY2024 | Mar 31, 2024 | -$61.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$46.30M | – |
| Q3 FY2023 | Sep 30, 2023 | -$46.45M | – |
| Q2 FY2023 | Jun 30, 2023 | -$44.22M | – |
| Q1 FY2023 | Mar 31, 2023 | -$49.57M | -136.9% |
| Q4 FY2022 | Dec 31, 2022 | -$49.69M | – |
| Q3 FY2022 | Sep 30, 2022 | -$50.97M | -111.5% |
| Q2 FY2022 | Jun 30, 2022 | -$58.19M | – |
| Q1 FY2022 | Mar 31, 2022 | $134.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$49.82M | – |
| Q3 FY2021 | Sep 30, 2021 | $444.14M | – |
| Q2 FY2021 | Jun 30, 2021 | -$45.37M | – |
| Q1 FY2021 | Mar 31, 2021 | -$53.64M | – |
| Q4 FY2020 | Dec 31, 2020 | -$48.45M | – |
| Q3 FY2020 | Sep 30, 2020 | -$41.20M | – |
| Q2 FY2020 | Jun 30, 2020 | -$46.24M | – |
| Q1 FY2020 | Mar 31, 2020 | -$35.88M | – |
| Q4 FY2019 | Dec 31, 2019 | -$30.40M | – |
| Q3 FY2019 | Sep 30, 2019 | -$31.16M | – |
| Q2 FY2019 | Jun 30, 2019 | -$27.42M | – |
| Q1 FY2019 | Mar 31, 2019 | -$25.60M | -113.9% |
| Q4 FY2018 | Dec 31, 2018 | -$18.07M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.52M | – |
| Q2 FY2018 | Jun 30, 2018 | -$17.75M | – |
| Q1 FY2018 | Mar 31, 2018 | $183.91M | – |
See a number that looks wrong?